Annexon Secures Strategic Credit Facility for Up to $200MM from Oxford Finance
Annexon, a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, entered into a strategic credit facility agreement with Oxford Finance for up to $200 million. “This strategic facility enhances our financial and operational capabilities as we prepare for the...
Read moreDetails

